Do You Need a License to Sell Peptides in Delaware?

There is no single credential called a "peptide license" in Delaware or in any other state. What licensing applies to your business depends entirely on which regulatory lane you are actually operating in: ordinary state and local business registration, wholesale distribution of drug products intended for human administration, or the research-use-only (RUO) supply lane that Real Peptides operates in. Those are three separate questions with three separate answers, and treating them as one question is the most common error a first-time buyer makes. Everything below is informational only — it is not legal advice, and the specifics for your entity, your catalog, and your customer base should be resolved with a Delaware-licensed attorney and the applicable state boards before you take a first order.

Three questions hiding inside one

When an operator asks whether they need a license, they are usually asking one of three things without separating them.

The first is the entity question: does the business need to be registered and authorized to do business in the state at all? That is the baseline question every company faces regardless of what it sells, and it has nothing specific to do with peptides. It is answered by the state's business registration framework and, in many cases, by local requirements as well.

The second is the drug-distribution question: does the product being sold fall into a category that triggers wholesale drug distributor licensing, pharmacy oversight, or professional practice rules? That question turns on what the product is and what it is intended for. Intent matters enormously here — how a product is labeled, marketed, and described is part of what determines the category it falls into. This is the question that most often needs a lawyer rather than a search engine.

The third is the research-supply question: what applies when a compound is sold as a research chemical, labeled not for human consumption, and supplied to businesses and laboratories for laboratory research use? This lane has its own documentation expectations, its own labeling discipline, and its own hard boundaries around claims.

A business can sit in more than one lane at once. A reseller building a research catalog is in the first and third. A licensed clinical operation is in a different position entirely, and its obligations flow from its clinical licensure, not from the peptide category. The practical takeaway is that you cannot answer "do I need a license" until you have decided precisely what your business is selling and to whom.

Questions worth putting to counsel before your first order

Rather than looking for a yes-or-no answer online, take a structured set of questions to a qualified attorney. The table below is a starting framework, not a determination of what any state requires.

The point of this exercise is not to reach a comfortable conclusion. It is to arrive at your attorney's office with the right questions already framed, which is faster and cheaper than arriving with none.

What research-use-only supply actually constrains

Research-use-only is not a marketing label or a disclaimer you paste at the bottom of a page. It is a description of what the product is and how it may be represented. Compounds supplied on an RUO basis are intended for laboratory research. They are not FDA-approved drugs, they are not sold for human consumption, and they carry no dosing information, administration guidance, or protocols — because providing that material would itself be a representation about use.

For a business buyer, this shapes three concrete things.

Your product copy. Every sentence on your storefront, in your email marketing, and in your sales conversations is evidence of intent. Research-use compounds can be described in terms of what the research literature has examined — research suggests certain peptide sequences are studied for particular signaling pathways, for example — without ever suggesting a person should take them.

Your labeling. Not-for-human-consumption labeling has to survive the whole chain, from the vial you receive to whatever you ship. Relabeling that strips or softens that language is a self-inflicted wound.

Your customer qualification. Who you sell to, and what you know about why they are buying, is part of your compliance posture. A wholesale program that asks qualifying questions is not being difficult; it is doing what a serious supply chain does.

None of this is unique to Delaware. It travels with the product category rather than the map.

The paperwork follows the product

Most problems that surface later are documentation problems, not chemistry problems. If a regulator, a payment processor, an insurer, or simply a demanding customer asks you to substantiate what you sold, the answer has to be retrievable.

That means keeping a supplier record that identifies who you bought from, on what terms, and under what representations. It means retaining certificates of analysis matched to the specific lot you received — not a generic COA for the compound in the abstract, but one tied to the batch number on the vial in your hand. It means being able to trace a unit you shipped back to the batch it came from, which requires that you actually record lot numbers at the point of sale rather than reconstructing them from memory.

This is also where a supplier's transparency becomes an operational asset rather than a nicety. If COAs are published and lot-referenced, your recordkeeping is a matter of saving a link and a number. If COAs are emailed on request, sold separately, or produced only in summary form, you are building a paper trail out of someone else's goodwill.

How to vet a supplier before the first purchase order

Supplier diligence is the part of this process you fully control, and it is where a buyer should spend real time.

Start with analytical method. Ask what method establishes purity and what threshold the supplier holds to. High-performance liquid chromatography is the standard analytical method for peptide purity; a supplier who cannot name a method has not answered the question.

Then ask about batch-level testing scope. Purity alone is one dimension. Multi-panel batch testing looks at a wider set of quality attributes, and the meaningful question is whether the panel is run per batch or once on a representative sample and reused indefinitely.

Ask whether COAs are publicly verifiable. This is the single fastest credibility filter in the category. If you can look up lab results yourself, without asking a salesperson, the supplier has accepted a standing verification burden. If COAs are gated, delayed, priced, or unavailable for the specific lot you received, treat that as information.

Ask about pricing structure. Hidden pricing that only appears after a sales call is common in this industry and is worth pushing back on. Tiered wholesale pricing should be explainable in plain terms before you commit, and minimums should be stated rather than negotiated case by case in a way you cannot compare.

Ask about fulfillment origin and lead time. Where orders ship from affects both timing and the documentation that accompanies them. Domestic fulfillment with a stated turnaround is materially different from an unspecified international lead time.

Finally, ask about catalog depth and consistency. A supplier who can hold quality across a broad range — from widely studied compounds through more specialized research categories — is a supplier you can grow with rather than replace. Browsing a supplier's popular peptides collection tells you quickly whether the catalog is a real inventory operation or a thin storefront.

Where new resellers create their own problems

A few patterns recur often enough to name.

The first is claims drift. A business starts with careful research-use language, then a marketing hire rewrites the product pages for conversion, and six months later the copy reads like a health promise. Claims language should be reviewed on a schedule, not written once.

The second is mixing categories. Bundling compounds with supplies in a way that presents a ready-to-use kit changes the story your catalog tells about intent, regardless of what your disclaimer says. Keep categories separate.

The third is assuming a supplier's compliance covers yours. It does not. A supplier's testing, labeling, and documentation give you a defensible input. What you do downstream — how you describe it, who you sell it to, what records you keep — is yours alone, and your counsel's domain.

What Real Peptides does differently

Real Peptides supplies research-use-only compounds to business buyers through its Wholesale Partner Program, and the program is built around removing the diligence gaps described above rather than asking buyers to take claims on trust.

Purity is held to a 99%+ HPLC standard, with multi-panel testing performed at the batch level rather than as a one-time exercise. Certificates of analysis are publicly verifiable — a prospective partner can check lab results directly instead of requesting them through a salesperson, and existing partners can match documentation to the lots they received. That verifiability is what makes the recordkeeping described earlier practical rather than aspirational.

Fulfillment runs from US stock on a stated 5–7 day window, which matters for inventory planning and for keeping documentation in a single domestic chain. Wholesale pricing is tiered and explained up front rather than revealed after a discovery call.

Qualification runs through a three-step wholesale application: submit business details, complete verification, and receive tier pricing and account access. It is a screening process by design. Real Peptides does not maintain facilities or staff in any particular city or state and does not supply GLP-1 class compounds such as semaglutide, tirzepatide or retatrutide, nor melanotan, through the wholesale program.

If your business qualifies

If you have separated the three licensing questions, taken the entity and category questions to a Delaware-licensed attorney, and satisfied yourself on supplier verifiability, the remaining step is qualification. The Wholesale Partner Program application is short, and the verification stage is where fit gets confirmed on both sides before any tier pricing is issued.

For more on program structure and pricing tiers, see the wholesale peptides program overview; for the general licensing framework beyond one state, see do you need a license to sell peptides; and when you are ready to be qualified, you can apply for a wholesale account.